title: Review of ONTARGET: treating patients at high risk for vascular events with telmisartan, ramipril, or both. Commentary.
authors.affiliation: Department of Emergency Medicine, Ohio State University, Columbus, OH 43212, USA. guthrie.1@osu.edu
authors.forename: Robert M
authors.initials: RM
authors.lastname: Guthrie